Table 4c.
Xenogeneic MSC therapy in DN preclinical studies.
| Model | Animal/ Strain | Treatment | Dose | Adm. route | Outcome | References |
|---|---|---|---|---|---|---|
| STZ–T1D | Rat SD |
hUDSC-Exosomes | 100 μg exosomes | IV (tail vein) |
↓Mesangial expansion, ↓glomeruli hypertrophy ↓Casp-3, and, ↓U-ACR (↑BMP-7, ↑VEGF, ↑TGF-ß and ↑angiogenin related) |
(197) |
| STZ–T1D | Rat SD |
hUCB-MNCs | 0.5 x106 cells | IV (tail vein) |
↓ EMT markers (↓α-SMA and ↑ E-cadherin) ↓ Fractional mesangial area in glomeruli |
(198) |
| STZ–T1D | Rat Albino | hUCB-MNCs | 150 x 106 cells | IV (tail vein) | ↓ECM deposition (↓laminin expression) ↓U-ACR, ↓Arterial pressure |
(199) |
| STZ–T1D | Mouse NOD.CB17-Prkdcscid/J | hBM-MSC | 2.5 x 106 cells (twice) | IC | ↓Blood glucose ↓Macrophages infiltration, ↓Mesangial ECM deposition ↑Insulin Engraftment detected in pancreatic and renal histology |
(84) |